Pharma Mar S.A. (PHM) - Net Assets

Latest as of December 2025: €251.83 Million EUR ≈ $294.42 Million USD

Based on the latest financial reports, Pharma Mar S.A. (PHM) has net assets worth €251.83 Million EUR (≈ $294.42 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€395.08 Million ≈ $461.89 Million USD) and total liabilities (€143.25 Million ≈ $167.47 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Pharma Mar S.A. to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets €251.83 Million
% of Total Assets 63.74%
Annual Growth Rate 1.8%
5-Year Change 41.54%
10-Year Change 419.3%
Growth Volatility 263.87

Pharma Mar S.A. - Net Assets Trend (2002–2025)

This chart illustrates how Pharma Mar S.A.'s net assets have evolved over time, based on quarterly financial data. Also explore PHM total asset value for the complete picture of this company's asset base.

Annual Net Assets for Pharma Mar S.A. (2002–2025)

The table below shows the annual net assets of Pharma Mar S.A. from 2002 to 2025. For live valuation and market cap data, see PHM company net worth.

Year Net Assets Change
2025-12-31 €251.83 Million
≈ $294.42 Million		 +20.86%
2024-12-31 €208.36 Million
≈ $243.59 Million		 +7.71%
2023-12-31 €193.44 Million
≈ $226.15 Million		 -13.24%
2022-12-31 €222.96 Million
≈ $260.66 Million		 +25.31%
2021-12-31 €177.92 Million
≈ $208.00 Million		 +73.20%
2020-12-31 €102.72 Million
≈ $120.09 Million		 +1277.71%
2019-12-31 €7.46 Million
≈ $8.72 Million		 -57.33%
2018-12-31 €17.47 Million
≈ $20.43 Million		 -23.98%
2017-12-31 €22.98 Million
≈ $26.87 Million		 -52.61%
2016-12-31 €48.49 Million
≈ $56.70 Million		 -33.60%
2015-12-31 €73.04 Million
≈ $85.39 Million		 +21.59%
2014-12-31 €60.07 Million
≈ $70.23 Million		 +21.51%
2013-12-31 €49.44 Million
≈ $57.79 Million		 +27.65%
2012-12-31 €38.73 Million
≈ $45.27 Million		 +12.24%
2011-12-31 €34.50 Million
≈ $40.34 Million		 -1.03%
2010-12-31 €34.86 Million
≈ $40.76 Million		 -15.26%
2009-12-31 €41.14 Million
≈ $48.09 Million		 -16.63%
2008-12-31 €49.34 Million
≈ $57.69 Million		 -50.06%
2007-12-31 €98.81 Million
≈ $115.52 Million		 -7.80%
2006-12-31 €107.17 Million
≈ $125.30 Million		 -70.23%
2005-12-31 €360.04 Million
≈ $420.93 Million		 +19.52%
2004-12-31 €301.23 Million
≈ $352.17 Million		 +116.28%
2003-12-31 €139.28 Million
≈ $162.83 Million		 -16.55%
2002-12-31 €166.90 Million
≈ $195.12 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Pharma Mar S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 29393800000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings €233.82 Million 92.85%
Common Stock €10.80 Million 4.29%
Other Comprehensive Income €18.00K 0.01%
Other Components €7.19 Million 2.86%
Total Equity €251.83 Million 100.00%

Pharma Mar S.A. Competitors by Market Cap

The table below lists competitors of Pharma Mar S.A. ranked by their market capitalization.

Company Market Cap
Oruka Therapeutics, Inc.
NASDAQ:ORKA
 $1.56 Billion
Hankook Tire Worldwide
KO:000240
 $1.56 Billion
CHOROKBAEM COMPANY Co. Ltd
KQ:052300
 $1.56 Billion
Beijing Jingwei Hirain Technologies Co. Ltd. A
SHG:688326
 $1.56 Billion
Nyfosa AB (publ)
ST:NYF
 $1.56 Billion
BlueNord ASA
OL:BNOR
 $1.56 Billion
DUERR AG UNSP.ADR 1/5
F:DUEB
 $1.56 Billion
Hope Bancorp Inc
NASDAQ:HOPE
 $1.56 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Pharma Mar S.A.'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 208,359,000 to 251,833,000, a change of 43,474,000 (20.9%).
  • Net income of 74,986,000 contributed positively to equity growth.
  • Dividend payments of 13,949,000 reduced retained earnings.
  • Share repurchases of 18,250,000 reduced equity.
  • New share issuances of 15,870,000 increased equity.
  • Other comprehensive income increased equity by 2,000.
  • Other factors decreased equity by 15,185,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income €74.99 Million +29.78%
Dividends Paid €13.95 Million -5.54%
Share Repurchases €18.25 Million -7.25%
Share Issuances €15.87 Million +6.3%
Other Comprehensive Income €2.00K +0.0%
Other Changes €-15.19 Million -6.03%
Total Change €- 20.86%

Book Value vs Market Value Analysis

This analysis compares Pharma Mar S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 7.06x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 10.35x to 7.06x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2002-12-31 €9.98 €103.30 x
2003-12-31 €8.33 €103.30 x
2004-12-31 €17.09 €103.30 x
2005-12-31 €21.22 €103.30 x
2006-12-31 €5.54 €103.30 x
2007-12-31 €5.33 €103.30 x
2008-12-31 €2.77 €103.30 x
2009-12-31 €2.25 €103.30 x
2010-12-31 €1.87 €103.30 x
2011-12-31 €2.14 €103.30 x
2012-12-31 €2.29 €103.30 x
2013-12-31 €2.89 €103.30 x
2014-12-31 €3.47 €103.30 x
2015-12-31 €4.17 €103.30 x
2016-12-31 €2.84 €103.30 x
2017-12-31 €1.46 €103.30 x
2018-12-31 €1.16 €103.30 x
2019-12-31 €0.62 €103.30 x
2020-12-31 €5.61 €103.30 x
2021-12-31 €9.84 €103.30 x
2022-12-31 €12.34 €103.30 x
2023-12-31 €10.80 €103.30 x
2024-12-31 €11.86 €103.30 x
2025-12-31 €14.63 €103.30 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Pharma Mar S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 29.78%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 33.87%
  • • Asset Turnover: 0.56x
  • • Equity Multiplier: 1.57x
  • Recent ROE (29.78%) is above the historical average (-11.39%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2002 -21.12% -53.52% 0.24x 1.63x €-51.95 Million
2003 -18.83% -32.64% 0.29x 1.98x €-40.15 Million
2004 0.45% 204.63% 0.00x 1.12x €-28.75 Million
2005 0.01% 8.92% 0.00x 1.09x €-35.96 Million
2006 -49.39% -63.81% 0.34x 2.28x €-58.50 Million
2007 -52.93% -59.29% 0.37x 2.43x €-60.24 Million
2008 -88.64% -41.55% 0.51x 4.21x €-48.67 Million
2009 -68.40% -22.80% 0.58x 5.14x €-32.25 Million
2010 -35.73% -8.03% 0.67x 6.69x €-15.78 Million
2011 -3.47% -0.90% 0.70x 5.51x €-5.33 Million
2012 15.58% 4.77% 0.69x 4.72x €2.36 Million
2013 21.27% 8.06% 0.74x 3.56x €6.00 Million
2014 20.53% 8.82% 0.74x 3.15x €6.73 Million
2015 8.57% 3.42% 0.91x 2.76x €-1.10 Million
2016 -45.99% -13.31% 0.82x 4.22x €-29.32 Million
2017 -99.55% -14.91% 0.96x 6.99x €-29.43 Million
2018 -25.90% -3.41% 1.03x 7.38x €-7.67 Million
2019 -80.71% -10.70% 0.69x 10.96x €-10.32 Million
2020 133.62% 50.85% 0.82x 3.22x €126.99 Million
2021 52.19% 40.40% 0.62x 2.07x €75.07 Million
2022 22.14% 25.14% 0.50x 1.76x €27.06 Million
2023 0.59% 0.72% 0.46x 1.76x €-18.21 Million
2024 12.54% 14.94% 0.50x 1.68x €5.29 Million
2025 29.78% 33.87% 0.56x 1.57x €49.80 Million

Industry Comparison

This section compares Pharma Mar S.A.'s net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $16,295,758
  • Average return on equity (ROE) among peers: -57.94%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Pharma Mar S.A. (PHM) €251.83 Million -21.12% 0.57x $1.56 Billion
Atrys Health SL (ATRY) $23.30 Million 1.25% 0.73x $214.84 Million
Biotechnology Assets S.A. (BST) $3.84 Million -223.94% 4.26x $13.52 Million
Oryzon Genomics SA (ORY) $34.43 Million -15.09% 0.77x $227.73 Million
Vytrus Biotech S.A. (VYT) $3.61 Million 6.01% 0.72x $88.79 Million

About Pharma Mar S.A.

MC:PHM Spain Biotechnology
Market Cap
$2.09 Billion
€1.79 Billion EUR
Market Cap Rank
#7271 Global
#57 in Spain
Share Price
€103.30
Change (1 day)
-0.29%
52-Week Range
€70.85 - €103.60
All Time High
€129.23
Categories
Companies in Spain Biotechnology
About

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound deri… Read more